nodes	percent_of_prediction	percent_of_DWPC	metapath
Tadalafil—Vaginal haemorrhage—Epirubicin—liver cancer	0.0059	0.00648	CcSEcCtD
Tadalafil—Urinary tract disorder—Sorafenib—liver cancer	0.00586	0.00643	CcSEcCtD
Tadalafil—Connective tissue disorder—Sorafenib—liver cancer	0.00583	0.0064	CcSEcCtD
Tadalafil—Urethral disorder—Sorafenib—liver cancer	0.00582	0.00638	CcSEcCtD
Tadalafil—Scotoma—Epirubicin—liver cancer	0.00575	0.00631	CcSEcCtD
Tadalafil—Erythema multiforme—Sorafenib—liver cancer	0.00561	0.00616	CcSEcCtD
Tadalafil—CYP3A4—Felbamate Metabolism—CYP2E1—liver cancer	0.00556	0.0629	CbGpPWpGaD
Tadalafil—Tinnitus—Sorafenib—liver cancer	0.00554	0.00607	CcSEcCtD
Tadalafil—Flushing—Sorafenib—liver cancer	0.00551	0.00604	CcSEcCtD
Tadalafil—Cardiac disorder—Sorafenib—liver cancer	0.00551	0.00604	CcSEcCtD
Tadalafil—Vaginal haemorrhage—Doxorubicin—liver cancer	0.00546	0.00599	CcSEcCtD
Tadalafil—Ventricular arrhythmia—Doxorubicin—liver cancer	0.00546	0.00599	CcSEcCtD
Tadalafil—Angiopathy—Sorafenib—liver cancer	0.00539	0.00591	CcSEcCtD
Tadalafil—Immune system disorder—Sorafenib—liver cancer	0.00536	0.00588	CcSEcCtD
Tadalafil—Mediastinal disorder—Sorafenib—liver cancer	0.00535	0.00587	CcSEcCtD
Tadalafil—Scotoma—Doxorubicin—liver cancer	0.00532	0.00584	CcSEcCtD
Tadalafil—Mental disorder—Sorafenib—liver cancer	0.0052	0.00571	CcSEcCtD
Tadalafil—Cardiovascular disorder—Epirubicin—liver cancer	0.00497	0.00546	CcSEcCtD
Tadalafil—Muscle spasms—Sorafenib—liver cancer	0.00497	0.00545	CcSEcCtD
Tadalafil—Bone disorder—Epirubicin—liver cancer	0.00484	0.00531	CcSEcCtD
Tadalafil—Rectal haemorrhage—Epirubicin—liver cancer	0.00484	0.00531	CcSEcCtD
Tadalafil—Lacrimation increased—Epirubicin—liver cancer	0.00474	0.0052	CcSEcCtD
Tadalafil—Angioedema—Sorafenib—liver cancer	0.00472	0.00518	CcSEcCtD
Tadalafil—Syncope—Sorafenib—liver cancer	0.00464	0.00508	CcSEcCtD
Tadalafil—Cardiovascular disorder—Doxorubicin—liver cancer	0.0046	0.00505	CcSEcCtD
Tadalafil—Loss of consciousness—Sorafenib—liver cancer	0.00454	0.00498	CcSEcCtD
Tadalafil—Cough—Sorafenib—liver cancer	0.00451	0.00495	CcSEcCtD
Tadalafil—Rectal haemorrhage—Doxorubicin—liver cancer	0.00448	0.00491	CcSEcCtD
Tadalafil—Bone disorder—Doxorubicin—liver cancer	0.00448	0.00491	CcSEcCtD
Tadalafil—Hypertension—Sorafenib—liver cancer	0.00446	0.0049	CcSEcCtD
Tadalafil—Neck pain—Epirubicin—liver cancer	0.00442	0.00485	CcSEcCtD
Tadalafil—Myalgia—Sorafenib—liver cancer	0.0044	0.00483	CcSEcCtD
Tadalafil—Arthralgia—Sorafenib—liver cancer	0.0044	0.00483	CcSEcCtD
Tadalafil—Lacrimation increased—Doxorubicin—liver cancer	0.00439	0.00481	CcSEcCtD
Tadalafil—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—liver cancer	0.00437	0.00479	CcSEcCtD
Tadalafil—Dry mouth—Sorafenib—liver cancer	0.0043	0.00472	CcSEcCtD
Tadalafil—Infection—Sorafenib—liver cancer	0.00419	0.0046	CcSEcCtD
Tadalafil—Shock—Sorafenib—liver cancer	0.00415	0.00455	CcSEcCtD
Tadalafil—Nervous system disorder—Sorafenib—liver cancer	0.00414	0.00454	CcSEcCtD
Tadalafil—Skin disorder—Sorafenib—liver cancer	0.0041	0.00449	CcSEcCtD
Tadalafil—Neck pain—Doxorubicin—liver cancer	0.00409	0.00449	CcSEcCtD
Tadalafil—Oesophagitis—Epirubicin—liver cancer	0.00399	0.00438	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Sorafenib—liver cancer	0.00384	0.00422	CcSEcCtD
Tadalafil—Dyspnoea—Sorafenib—liver cancer	0.00376	0.00413	CcSEcCtD
Tadalafil—Dyspepsia—Sorafenib—liver cancer	0.00371	0.00407	CcSEcCtD
Tadalafil—Oesophagitis—Doxorubicin—liver cancer	0.00369	0.00405	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Sorafenib—liver cancer	0.00364	0.00399	CcSEcCtD
Tadalafil—Fatigue—Sorafenib—liver cancer	0.00364	0.00399	CcSEcCtD
Tadalafil—Constipation—Sorafenib—liver cancer	0.00361	0.00396	CcSEcCtD
Tadalafil—Pain—Sorafenib—liver cancer	0.00361	0.00396	CcSEcCtD
Tadalafil—Eye pain—Epirubicin—liver cancer	0.00351	0.00385	CcSEcCtD
Tadalafil—Gastrointestinal pain—Sorafenib—liver cancer	0.00345	0.00378	CcSEcCtD
Tadalafil—Hot flush—Epirubicin—liver cancer	0.00339	0.00372	CcSEcCtD
Tadalafil—Dermatitis exfoliative—Epirubicin—liver cancer	0.00336	0.00369	CcSEcCtD
Tadalafil—Menopausal symptoms—Epirubicin—liver cancer	0.00336	0.00369	CcSEcCtD
Tadalafil—Urticaria—Sorafenib—liver cancer	0.00335	0.00368	CcSEcCtD
Tadalafil—CYP3A4—Liver X Receptor Pathway—SCD—liver cancer	0.00334	0.0378	CbGpPWpGaD
Tadalafil—Abdominal pain—Sorafenib—liver cancer	0.00333	0.00366	CcSEcCtD
Tadalafil—Renal impairment—Epirubicin—liver cancer	0.00333	0.00366	CcSEcCtD
Tadalafil—Eye pain—Doxorubicin—liver cancer	0.00325	0.00357	CcSEcCtD
Tadalafil—Cerebrovascular accident—Epirubicin—liver cancer	0.00324	0.00355	CcSEcCtD
Tadalafil—Pain in extremity—Epirubicin—liver cancer	0.00317	0.00348	CcSEcCtD
Tadalafil—Hot flush—Doxorubicin—liver cancer	0.00314	0.00344	CcSEcCtD
Tadalafil—Migraine—Epirubicin—liver cancer	0.00312	0.00342	CcSEcCtD
Tadalafil—Menopausal symptoms—Doxorubicin—liver cancer	0.00311	0.00341	CcSEcCtD
Tadalafil—Dermatitis exfoliative—Doxorubicin—liver cancer	0.00311	0.00341	CcSEcCtD
Tadalafil—Hypersensitivity—Sorafenib—liver cancer	0.00311	0.00341	CcSEcCtD
Tadalafil—Renal impairment—Doxorubicin—liver cancer	0.00308	0.00338	CcSEcCtD
Tadalafil—Face oedema—Epirubicin—liver cancer	0.00306	0.00336	CcSEcCtD
Tadalafil—Asthenia—Sorafenib—liver cancer	0.00303	0.00332	CcSEcCtD
Tadalafil—Cerebrovascular accident—Doxorubicin—liver cancer	0.003	0.00329	CcSEcCtD
Tadalafil—Pruritus—Sorafenib—liver cancer	0.00298	0.00327	CcSEcCtD
Tadalafil—Pain in extremity—Doxorubicin—liver cancer	0.00294	0.00322	CcSEcCtD
Tadalafil—Liver function test abnormal—Epirubicin—liver cancer	0.00293	0.00321	CcSEcCtD
Tadalafil—Orthostatic hypotension—Epirubicin—liver cancer	0.0029	0.00318	CcSEcCtD
Tadalafil—Abdominal pain upper—Epirubicin—liver cancer	0.0029	0.00318	CcSEcCtD
Tadalafil—Migraine—Doxorubicin—liver cancer	0.00289	0.00317	CcSEcCtD
Tadalafil—Diarrhoea—Sorafenib—liver cancer	0.00289	0.00317	CcSEcCtD
Tadalafil—Breast disorder—Epirubicin—liver cancer	0.00287	0.00314	CcSEcCtD
Tadalafil—Nasopharyngitis—Epirubicin—liver cancer	0.00284	0.00311	CcSEcCtD
Tadalafil—Face oedema—Doxorubicin—liver cancer	0.00283	0.00311	CcSEcCtD
Tadalafil—Gastritis—Epirubicin—liver cancer	0.00281	0.00308	CcSEcCtD
Tadalafil—Dizziness—Sorafenib—liver cancer	0.00279	0.00306	CcSEcCtD
Tadalafil—Influenza—Epirubicin—liver cancer	0.00274	0.00301	CcSEcCtD
Tadalafil—Dysphagia—Epirubicin—liver cancer	0.00274	0.00301	CcSEcCtD
Tadalafil—Liver function test abnormal—Doxorubicin—liver cancer	0.00271	0.00297	CcSEcCtD
Tadalafil—Vomiting—Sorafenib—liver cancer	0.00268	0.00294	CcSEcCtD
Tadalafil—Orthostatic hypotension—Doxorubicin—liver cancer	0.00268	0.00294	CcSEcCtD
Tadalafil—Abdominal pain upper—Doxorubicin—liver cancer	0.00268	0.00294	CcSEcCtD
Tadalafil—Angina pectoris—Epirubicin—liver cancer	0.00267	0.00293	CcSEcCtD
Tadalafil—Rash—Sorafenib—liver cancer	0.00266	0.00292	CcSEcCtD
Tadalafil—Dermatitis—Sorafenib—liver cancer	0.00266	0.00291	CcSEcCtD
Tadalafil—Breast disorder—Doxorubicin—liver cancer	0.00265	0.00291	CcSEcCtD
Tadalafil—Headache—Sorafenib—liver cancer	0.00264	0.0029	CcSEcCtD
Tadalafil—Bronchitis—Epirubicin—liver cancer	0.00264	0.00289	CcSEcCtD
Tadalafil—Nasopharyngitis—Doxorubicin—liver cancer	0.00262	0.00288	CcSEcCtD
Tadalafil—Gastritis—Doxorubicin—liver cancer	0.0026	0.00285	CcSEcCtD
Tadalafil—Upper respiratory tract infection—Epirubicin—liver cancer	0.00255	0.00279	CcSEcCtD
Tadalafil—Dysphagia—Doxorubicin—liver cancer	0.00254	0.00278	CcSEcCtD
Tadalafil—Influenza—Doxorubicin—liver cancer	0.00254	0.00278	CcSEcCtD
Tadalafil—Nausea—Sorafenib—liver cancer	0.00251	0.00275	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—HBE1—liver cancer	0.0025	0.0283	CbGpPWpGaD
Tadalafil—Angina pectoris—Doxorubicin—liver cancer	0.00247	0.00271	CcSEcCtD
Tadalafil—Infestation—Epirubicin—liver cancer	0.00244	0.00268	CcSEcCtD
Tadalafil—Infestation NOS—Epirubicin—liver cancer	0.00244	0.00268	CcSEcCtD
Tadalafil—Bronchitis—Doxorubicin—liver cancer	0.00244	0.00268	CcSEcCtD
Tadalafil—Stevens-Johnson syndrome—Epirubicin—liver cancer	0.00242	0.00266	CcSEcCtD
Tadalafil—Renal failure—Epirubicin—liver cancer	0.0024	0.00264	CcSEcCtD
Tadalafil—Conjunctivitis—Epirubicin—liver cancer	0.00238	0.00261	CcSEcCtD
Tadalafil—Urinary tract infection—Epirubicin—liver cancer	0.00238	0.00261	CcSEcCtD
Tadalafil—Upper respiratory tract infection—Doxorubicin—liver cancer	0.00236	0.00259	CcSEcCtD
Tadalafil—Sweating—Epirubicin—liver cancer	0.00234	0.00257	CcSEcCtD
Tadalafil—Haematuria—Epirubicin—liver cancer	0.00233	0.00256	CcSEcCtD
Tadalafil—Epistaxis—Epirubicin—liver cancer	0.00231	0.00253	CcSEcCtD
Tadalafil—Infestation NOS—Doxorubicin—liver cancer	0.00226	0.00248	CcSEcCtD
Tadalafil—Infestation—Doxorubicin—liver cancer	0.00226	0.00248	CcSEcCtD
Tadalafil—Stevens-Johnson syndrome—Doxorubicin—liver cancer	0.00224	0.00246	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—HBE1—liver cancer	0.00222	0.0252	CbGpPWpGaD
Tadalafil—Renal failure—Doxorubicin—liver cancer	0.00222	0.00244	CcSEcCtD
Tadalafil—Haemoglobin—Epirubicin—liver cancer	0.00221	0.00242	CcSEcCtD
Tadalafil—Rhinitis—Epirubicin—liver cancer	0.0022	0.00241	CcSEcCtD
Tadalafil—Conjunctivitis—Doxorubicin—liver cancer	0.0022	0.00241	CcSEcCtD
Tadalafil—Urinary tract infection—Doxorubicin—liver cancer	0.0022	0.00241	CcSEcCtD
Tadalafil—Haemorrhage—Epirubicin—liver cancer	0.00219	0.00241	CcSEcCtD
Tadalafil—Hypoaesthesia—Epirubicin—liver cancer	0.00218	0.00239	CcSEcCtD
Tadalafil—Pharyngitis—Epirubicin—liver cancer	0.00218	0.00239	CcSEcCtD
Tadalafil—Sweating—Doxorubicin—liver cancer	0.00217	0.00238	CcSEcCtD
Tadalafil—Urinary tract disorder—Epirubicin—liver cancer	0.00217	0.00238	CcSEcCtD
Tadalafil—Oedema peripheral—Epirubicin—liver cancer	0.00216	0.00237	CcSEcCtD
Tadalafil—Haematuria—Doxorubicin—liver cancer	0.00216	0.00237	CcSEcCtD
Tadalafil—Connective tissue disorder—Epirubicin—liver cancer	0.00216	0.00237	CcSEcCtD
Tadalafil—PDE11A—Platelet homeostasis—MAPK14—liver cancer	0.00215	0.0244	CbGpPWpGaD
Tadalafil—Urethral disorder—Epirubicin—liver cancer	0.00215	0.00236	CcSEcCtD
Tadalafil—Epistaxis—Doxorubicin—liver cancer	0.00213	0.00234	CcSEcCtD
Tadalafil—Erythema multiforme—Epirubicin—liver cancer	0.00207	0.00228	CcSEcCtD
Tadalafil—Eye disorder—Epirubicin—liver cancer	0.00205	0.00225	CcSEcCtD
Tadalafil—Tinnitus—Epirubicin—liver cancer	0.00205	0.00224	CcSEcCtD
Tadalafil—Haemoglobin—Doxorubicin—liver cancer	0.00204	0.00224	CcSEcCtD
Tadalafil—Flushing—Epirubicin—liver cancer	0.00204	0.00223	CcSEcCtD
Tadalafil—Cardiac disorder—Epirubicin—liver cancer	0.00204	0.00223	CcSEcCtD
Tadalafil—Rhinitis—Doxorubicin—liver cancer	0.00204	0.00223	CcSEcCtD
Tadalafil—Haemorrhage—Doxorubicin—liver cancer	0.00203	0.00223	CcSEcCtD
Tadalafil—Hypoaesthesia—Doxorubicin—liver cancer	0.00202	0.00222	CcSEcCtD
Tadalafil—Pharyngitis—Doxorubicin—liver cancer	0.00202	0.00221	CcSEcCtD
Tadalafil—Urinary tract disorder—Doxorubicin—liver cancer	0.00201	0.0022	CcSEcCtD
Tadalafil—Oedema peripheral—Doxorubicin—liver cancer	0.002	0.00219	CcSEcCtD
Tadalafil—Connective tissue disorder—Doxorubicin—liver cancer	0.002	0.00219	CcSEcCtD
Tadalafil—Angiopathy—Epirubicin—liver cancer	0.00199	0.00218	CcSEcCtD
Tadalafil—Urethral disorder—Doxorubicin—liver cancer	0.00199	0.00218	CcSEcCtD
Tadalafil—Immune system disorder—Epirubicin—liver cancer	0.00198	0.00217	CcSEcCtD
Tadalafil—Mediastinal disorder—Epirubicin—liver cancer	0.00198	0.00217	CcSEcCtD
Tadalafil—Mental disorder—Epirubicin—liver cancer	0.00192	0.00211	CcSEcCtD
Tadalafil—Erythema multiforme—Doxorubicin—liver cancer	0.00192	0.00211	CcSEcCtD
Tadalafil—PDE5A—Platelet homeostasis—MAPK14—liver cancer	0.00192	0.0217	CbGpPWpGaD
Tadalafil—Eye disorder—Doxorubicin—liver cancer	0.0019	0.00208	CcSEcCtD
Tadalafil—Tinnitus—Doxorubicin—liver cancer	0.00189	0.00208	CcSEcCtD
Tadalafil—Flushing—Doxorubicin—liver cancer	0.00188	0.00207	CcSEcCtD
Tadalafil—Cardiac disorder—Doxorubicin—liver cancer	0.00188	0.00207	CcSEcCtD
Tadalafil—Back pain—Epirubicin—liver cancer	0.00185	0.00203	CcSEcCtD
Tadalafil—Angiopathy—Doxorubicin—liver cancer	0.00184	0.00202	CcSEcCtD
Tadalafil—CYP3A4—Drug Induction of Bile Acid Pathway—NR1H4—liver cancer	0.00184	0.0208	CbGpPWpGaD
Tadalafil—Muscle spasms—Epirubicin—liver cancer	0.00184	0.00201	CcSEcCtD
Tadalafil—Immune system disorder—Doxorubicin—liver cancer	0.00183	0.00201	CcSEcCtD
Tadalafil—Mediastinal disorder—Doxorubicin—liver cancer	0.00183	0.00201	CcSEcCtD
Tadalafil—CYP3A4—Drug Induction of Bile Acid Pathway—NR1I3—liver cancer	0.00181	0.0205	CbGpPWpGaD
Tadalafil—Vision blurred—Epirubicin—liver cancer	0.0018	0.00197	CcSEcCtD
Tadalafil—Mental disorder—Doxorubicin—liver cancer	0.00178	0.00195	CcSEcCtD
Tadalafil—Vertigo—Epirubicin—liver cancer	0.00172	0.00188	CcSEcCtD
Tadalafil—Syncope—Epirubicin—liver cancer	0.00171	0.00188	CcSEcCtD
Tadalafil—Back pain—Doxorubicin—liver cancer	0.00171	0.00188	CcSEcCtD
Tadalafil—Muscle spasms—Doxorubicin—liver cancer	0.0017	0.00186	CcSEcCtD
Tadalafil—Palpitations—Epirubicin—liver cancer	0.00169	0.00185	CcSEcCtD
Tadalafil—CYP3A4—Farnesoid X Receptor  Pathway—NR1H4—liver cancer	0.00168	0.0191	CbGpPWpGaD
Tadalafil—Loss of consciousness—Epirubicin—liver cancer	0.00168	0.00184	CcSEcCtD
Tadalafil—Cough—Epirubicin—liver cancer	0.00167	0.00183	CcSEcCtD
Tadalafil—Vision blurred—Doxorubicin—liver cancer	0.00167	0.00183	CcSEcCtD
Tadalafil—Convulsion—Epirubicin—liver cancer	0.00166	0.00182	CcSEcCtD
Tadalafil—Hypertension—Epirubicin—liver cancer	0.00165	0.00181	CcSEcCtD
Tadalafil—Arthralgia—Epirubicin—liver cancer	0.00163	0.00178	CcSEcCtD
Tadalafil—Chest pain—Epirubicin—liver cancer	0.00163	0.00178	CcSEcCtD
Tadalafil—Myalgia—Epirubicin—liver cancer	0.00163	0.00178	CcSEcCtD
Tadalafil—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—liver cancer	0.00162	0.00177	CcSEcCtD
Tadalafil—Discomfort—Epirubicin—liver cancer	0.00161	0.00176	CcSEcCtD
Tadalafil—Dry mouth—Epirubicin—liver cancer	0.00159	0.00174	CcSEcCtD
Tadalafil—Vertigo—Doxorubicin—liver cancer	0.00159	0.00174	CcSEcCtD
Tadalafil—Syncope—Doxorubicin—liver cancer	0.00159	0.00174	CcSEcCtD
Tadalafil—Palpitations—Doxorubicin—liver cancer	0.00156	0.00171	CcSEcCtD
Tadalafil—Oedema—Epirubicin—liver cancer	0.00156	0.00171	CcSEcCtD
Tadalafil—Loss of consciousness—Doxorubicin—liver cancer	0.00155	0.0017	CcSEcCtD
Tadalafil—Infection—Epirubicin—liver cancer	0.00155	0.0017	CcSEcCtD
Tadalafil—CYP3A4—Aflatoxin B1 metabolism—GSTM1—liver cancer	0.00155	0.0175	CbGpPWpGaD
Tadalafil—Cough—Doxorubicin—liver cancer	0.00154	0.00169	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—ANXA2—liver cancer	0.00154	0.0175	CbGpPWpGaD
Tadalafil—Shock—Epirubicin—liver cancer	0.00153	0.00168	CcSEcCtD
Tadalafil—Convulsion—Doxorubicin—liver cancer	0.00153	0.00168	CcSEcCtD
Tadalafil—Nervous system disorder—Epirubicin—liver cancer	0.00153	0.00168	CcSEcCtD
Tadalafil—Hypertension—Doxorubicin—liver cancer	0.00153	0.00167	CcSEcCtD
Tadalafil—Tachycardia—Epirubicin—liver cancer	0.00152	0.00167	CcSEcCtD
Tadalafil—Skin disorder—Epirubicin—liver cancer	0.00151	0.00166	CcSEcCtD
Tadalafil—Hyperhidrosis—Epirubicin—liver cancer	0.00151	0.00165	CcSEcCtD
Tadalafil—Myalgia—Doxorubicin—liver cancer	0.0015	0.00165	CcSEcCtD
Tadalafil—Chest pain—Doxorubicin—liver cancer	0.0015	0.00165	CcSEcCtD
Tadalafil—Arthralgia—Doxorubicin—liver cancer	0.0015	0.00165	CcSEcCtD
Tadalafil—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—liver cancer	0.00149	0.00164	CcSEcCtD
Tadalafil—CYP3A4—Estrogen metabolism—GSTA1—liver cancer	0.00149	0.0168	CbGpPWpGaD
Tadalafil—Discomfort—Doxorubicin—liver cancer	0.00149	0.00163	CcSEcCtD
Tadalafil—Dry mouth—Doxorubicin—liver cancer	0.00147	0.00161	CcSEcCtD
Tadalafil—Hypotension—Epirubicin—liver cancer	0.00146	0.0016	CcSEcCtD
Tadalafil—Oedema—Doxorubicin—liver cancer	0.00144	0.00158	CcSEcCtD
Tadalafil—Infection—Doxorubicin—liver cancer	0.00143	0.00157	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Epirubicin—liver cancer	0.00142	0.00156	CcSEcCtD
Tadalafil—Shock—Doxorubicin—liver cancer	0.00142	0.00156	CcSEcCtD
Tadalafil—Nervous system disorder—Doxorubicin—liver cancer	0.00141	0.00155	CcSEcCtD
Tadalafil—Insomnia—Epirubicin—liver cancer	0.00141	0.00155	CcSEcCtD
Tadalafil—Tachycardia—Doxorubicin—liver cancer	0.00141	0.00154	CcSEcCtD
Tadalafil—Skin disorder—Doxorubicin—liver cancer	0.0014	0.00154	CcSEcCtD
Tadalafil—Paraesthesia—Epirubicin—liver cancer	0.0014	0.00154	CcSEcCtD
Tadalafil—Hyperhidrosis—Doxorubicin—liver cancer	0.00139	0.00153	CcSEcCtD
Tadalafil—Dyspnoea—Epirubicin—liver cancer	0.00139	0.00152	CcSEcCtD
Tadalafil—Somnolence—Epirubicin—liver cancer	0.00139	0.00152	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—ANXA2—liver cancer	0.00137	0.0156	CbGpPWpGaD
Tadalafil—Dyspepsia—Epirubicin—liver cancer	0.00137	0.00151	CcSEcCtD
Tadalafil—Hypotension—Doxorubicin—liver cancer	0.00135	0.00148	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Epirubicin—liver cancer	0.00135	0.00148	CcSEcCtD
Tadalafil—Fatigue—Epirubicin—liver cancer	0.00134	0.00147	CcSEcCtD
Tadalafil—Pain—Epirubicin—liver cancer	0.00133	0.00146	CcSEcCtD
Tadalafil—Constipation—Epirubicin—liver cancer	0.00133	0.00146	CcSEcCtD
Tadalafil—Musculoskeletal discomfort—Doxorubicin—liver cancer	0.00131	0.00144	CcSEcCtD
Tadalafil—Insomnia—Doxorubicin—liver cancer	0.0013	0.00143	CcSEcCtD
Tadalafil—Paraesthesia—Doxorubicin—liver cancer	0.0013	0.00142	CcSEcCtD
Tadalafil—Dyspnoea—Doxorubicin—liver cancer	0.00129	0.00141	CcSEcCtD
Tadalafil—Somnolence—Doxorubicin—liver cancer	0.00128	0.00141	CcSEcCtD
Tadalafil—Gastrointestinal pain—Epirubicin—liver cancer	0.00127	0.0014	CcSEcCtD
Tadalafil—Dyspepsia—Doxorubicin—liver cancer	0.00127	0.00139	CcSEcCtD
Tadalafil—Gastrointestinal disorder—Doxorubicin—liver cancer	0.00125	0.00137	CcSEcCtD
Tadalafil—Fatigue—Doxorubicin—liver cancer	0.00124	0.00136	CcSEcCtD
Tadalafil—Urticaria—Epirubicin—liver cancer	0.00124	0.00136	CcSEcCtD
Tadalafil—Pain—Doxorubicin—liver cancer	0.00123	0.00135	CcSEcCtD
Tadalafil—Constipation—Doxorubicin—liver cancer	0.00123	0.00135	CcSEcCtD
Tadalafil—Abdominal pain—Epirubicin—liver cancer	0.00123	0.00135	CcSEcCtD
Tadalafil—CYP3A4—Benzo(a)pyrene metabolism—CYP1A1—liver cancer	0.0012	0.0136	CbGpPWpGaD
Tadalafil—Gastrointestinal pain—Doxorubicin—liver cancer	0.00118	0.00129	CcSEcCtD
Tadalafil—Hypersensitivity—Epirubicin—liver cancer	0.00115	0.00126	CcSEcCtD
Tadalafil—Urticaria—Doxorubicin—liver cancer	0.00115	0.00126	CcSEcCtD
Tadalafil—Abdominal pain—Doxorubicin—liver cancer	0.00114	0.00125	CcSEcCtD
Tadalafil—Asthenia—Epirubicin—liver cancer	0.00112	0.00123	CcSEcCtD
Tadalafil—Pruritus—Epirubicin—liver cancer	0.0011	0.00121	CcSEcCtD
Tadalafil—CYP3A4—Constitutive Androstane Receptor Pathway—NR1I3—liver cancer	0.00109	0.0124	CbGpPWpGaD
Tadalafil—Diarrhoea—Epirubicin—liver cancer	0.00107	0.00117	CcSEcCtD
Tadalafil—Hypersensitivity—Doxorubicin—liver cancer	0.00106	0.00117	CcSEcCtD
Tadalafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1H4—liver cancer	0.00106	0.012	CbGpPWpGaD
Tadalafil—CYP3A4—Fatty Acid Omega Oxidation—CYP2E1—liver cancer	0.00105	0.0119	CbGpPWpGaD
Tadalafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I3—liver cancer	0.00104	0.0118	CbGpPWpGaD
Tadalafil—Asthenia—Doxorubicin—liver cancer	0.00103	0.00114	CcSEcCtD
Tadalafil—Dizziness—Epirubicin—liver cancer	0.00103	0.00113	CcSEcCtD
Tadalafil—PDE11A—Hemostasis—SERPINA1—liver cancer	0.00102	0.0116	CbGpPWpGaD
Tadalafil—Pruritus—Doxorubicin—liver cancer	0.00102	0.00112	CcSEcCtD
Tadalafil—PDE11A—Signaling Pathways—CHN2—liver cancer	0.000995	0.0113	CbGpPWpGaD
Tadalafil—Vomiting—Epirubicin—liver cancer	0.000991	0.00109	CcSEcCtD
Tadalafil—Diarrhoea—Doxorubicin—liver cancer	0.000987	0.00108	CcSEcCtD
Tadalafil—Rash—Epirubicin—liver cancer	0.000983	0.00108	CcSEcCtD
Tadalafil—Dermatitis—Epirubicin—liver cancer	0.000982	0.00108	CcSEcCtD
Tadalafil—Headache—Epirubicin—liver cancer	0.000977	0.00107	CcSEcCtD
Tadalafil—CYP3A4—Constitutive Androstane Receptor Pathway—GSTA2—liver cancer	0.000973	0.011	CbGpPWpGaD
Tadalafil—Dizziness—Doxorubicin—liver cancer	0.000954	0.00105	CcSEcCtD
Tadalafil—Nausea—Epirubicin—liver cancer	0.000926	0.00102	CcSEcCtD
Tadalafil—Vomiting—Doxorubicin—liver cancer	0.000917	0.00101	CcSEcCtD
Tadalafil—PDE5A—Hemostasis—SERPINA1—liver cancer	0.00091	0.0103	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IFT88—liver cancer	0.00091	0.0103	CbGpPWpGaD
Tadalafil—Rash—Doxorubicin—liver cancer	0.00091	0.000998	CcSEcCtD
Tadalafil—Dermatitis—Doxorubicin—liver cancer	0.000909	0.000997	CcSEcCtD
Tadalafil—Headache—Doxorubicin—liver cancer	0.000904	0.000991	CcSEcCtD
Tadalafil—CYP3A4—Xenobiotics—CYP2E1—liver cancer	0.000881	0.00997	CbGpPWpGaD
Tadalafil—Nausea—Doxorubicin—liver cancer	0.000857	0.00094	CcSEcCtD
Tadalafil—CYP3A4—Tamoxifen metabolism—CYP2E1—liver cancer	0.000847	0.00959	CbGpPWpGaD
Tadalafil—CYP3A4—Aflatoxin activation and detoxification—GGT1—liver cancer	0.000843	0.00954	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—TRIO—liver cancer	0.00077	0.00872	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—IFNA1—liver cancer	0.000761	0.00861	CbGpPWpGaD
Tadalafil—CYP3A4—Fatty Acid Omega Oxidation—CYP1A1—liver cancer	0.000756	0.00856	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—CCR4—liver cancer	0.000739	0.00836	CbGpPWpGaD
Tadalafil—CYP3A4—Estrogen metabolism—GSTM1—liver cancer	0.000726	0.00822	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—TRIO—liver cancer	0.0007	0.00792	CbGpPWpGaD
Tadalafil—CYP3A4—Estrogen metabolism—CYP1A1—liver cancer	0.000688	0.00779	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—IFNA1—liver cancer	0.000678	0.00768	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—PRKCE—liver cancer	0.000673	0.00762	CbGpPWpGaD
Tadalafil—CYP3A4—Cytochrome P450 - arranged by substrate type—NR1H4—liver cancer	0.000671	0.0076	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—CCR4—liver cancer	0.000671	0.00759	CbGpPWpGaD
Tadalafil—CYP3A4—Irinotecan Pathway—APC—liver cancer	0.000659	0.00746	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—ABL1—liver cancer	0.00064	0.00725	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—IGF2—liver cancer	0.000637	0.00722	CbGpPWpGaD
Tadalafil—CYP3A4—Xenobiotics—CYP1A1—liver cancer	0.000633	0.00716	CbGpPWpGaD
Tadalafil—CYP3A4—Tamoxifen metabolism—CYP1A1—liver cancer	0.000609	0.00689	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—HGF—liver cancer	0.000602	0.00682	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—PRKCE—liver cancer	0.0006	0.00679	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—CSF2—liver cancer	0.000595	0.00674	CbGpPWpGaD
Tadalafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP2E1—liver cancer	0.000576	0.00652	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—ABL1—liver cancer	0.000571	0.00646	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—IGF2—liver cancer	0.000568	0.00643	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—SHC3—liver cancer	0.000558	0.00632	CbGpPWpGaD
Tadalafil—CYP3A4—Phase 1 - Functionalization of compounds—NR1H4—liver cancer	0.000544	0.00616	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—HGF—liver cancer	0.000537	0.00607	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—CSF2—liver cancer	0.000531	0.00601	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—UGDH—liver cancer	0.000495	0.0056	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—MAPK14—liver cancer	0.000482	0.00546	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—F2—liver cancer	0.000467	0.00529	CbGpPWpGaD
Tadalafil—CYP3A4—Tryptophan metabolism—CYP2E1—liver cancer	0.000452	0.00512	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—PIK3CG—liver cancer	0.000447	0.00506	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—FST—liver cancer	0.000433	0.0049	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—MAPK14—liver cancer	0.00043	0.00486	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—PRKCE—liver cancer	0.000425	0.00481	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—F2—liver cancer	0.000416	0.00471	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—TRIO—liver cancer	0.000413	0.00468	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—PIK3CG—liver cancer	0.000398	0.00451	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CCR4—liver cancer	0.000396	0.00449	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—PIK3CD—liver cancer	0.000393	0.00445	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—SERPINE1—liver cancer	0.000389	0.0044	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—ALB—liver cancer	0.000388	0.00439	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—PRKCE—liver cancer	0.000386	0.00437	CbGpPWpGaD
Tadalafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARA—liver cancer	0.000379	0.00429	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—CSF2—liver cancer	0.000376	0.00426	CbGpPWpGaD
Tadalafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP2E1—liver cancer	0.000366	0.00414	CbGpPWpGaD
Tadalafil—CYP3A4—Oxidation by Cytochrome P450—CYP2E1—liver cancer	0.000361	0.00409	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—RAF1—liver cancer	0.000351	0.00397	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—PIK3CD—liver cancer	0.00035	0.00397	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—SERPINE1—liver cancer	0.000346	0.00392	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—ALB—liver cancer	0.000346	0.00391	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—PIK3CB—liver cancer	0.000343	0.00388	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—CSF2—liver cancer	0.000342	0.00387	CbGpPWpGaD
Tadalafil—CYP3A4—Tryptophan metabolism—CYP1A1—liver cancer	0.000325	0.00368	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—IL2—liver cancer	0.000315	0.00356	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—ADAM17—liver cancer	0.000313	0.00355	CbGpPWpGaD
Tadalafil—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—liver cancer	0.000313	0.00354	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—RAF1—liver cancer	0.000313	0.00354	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—PIK3CB—liver cancer	0.000305	0.00346	CbGpPWpGaD
Tadalafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP2E1—liver cancer	0.000296	0.00336	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—F2—liver cancer	0.000295	0.00334	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PSMD10—liver cancer	0.000294	0.00333	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PSMA4—liver cancer	0.000294	0.00333	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—NR1H4—liver cancer	0.000289	0.00327	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—GSTA3—liver cancer	0.000284	0.00322	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—PIK3CG—liver cancer	0.000283	0.0032	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—IL2—liver cancer	0.00028	0.00317	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—GSTA3—liver cancer	0.00028	0.00317	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—F2—liver cancer	0.000268	0.00303	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—VEGFA—liver cancer	0.000267	0.00303	CbGpPWpGaD
Tadalafil—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1A1—liver cancer	0.000263	0.00297	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—GSTA4—liver cancer	0.00026	0.00294	CbGpPWpGaD
Tadalafil—CYP3A4—Oxidation by Cytochrome P450—CYP1A1—liver cancer	0.000259	0.00294	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—PIK3CG—liver cancer	0.000257	0.0029	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—GSTA4—liver cancer	0.000256	0.0029	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—GSTA2—liver cancer	0.000253	0.00287	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—PIK3CD—liver cancer	0.000248	0.00281	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—TGFB1—liver cancer	0.000245	0.00278	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—GSTA1—liver cancer	0.000244	0.00277	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—NAT2—liver cancer	0.000242	0.00274	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—NAT2—liver cancer	0.000238	0.0027	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—VEGFA—liver cancer	0.000238	0.0027	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PRKCE—liver cancer	0.000228	0.00258	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—KRAS—liver cancer	0.000227	0.00257	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—PIK3CD—liver cancer	0.000226	0.00255	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—TGFB1—liver cancer	0.000219	0.00248	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—PIK3CB—liver cancer	0.000216	0.00245	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IGF2—liver cancer	0.000216	0.00245	CbGpPWpGaD
Tadalafil—CYP3A4—Phase 1 - Functionalization of compounds—CYP1A1—liver cancer	0.000213	0.00241	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—PIK3CA—liver cancer	0.000209	0.00236	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—GPX3—liver cancer	0.000203	0.00229	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—KRAS—liver cancer	0.000203	0.00229	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—TP53—liver cancer	0.000202	0.00229	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CSF2—liver cancer	0.000202	0.00228	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—RAF1—liver cancer	0.000201	0.00228	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—H2AFX—liver cancer	0.000199	0.00225	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—IL2—liver cancer	0.000199	0.00225	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—PIK3CB—liver cancer	0.000197	0.00223	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—HPGDS—liver cancer	0.000193	0.00219	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—HRAS—liver cancer	0.000193	0.00219	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—PIK3CA—liver cancer	0.000186	0.00211	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—IL2—liver cancer	0.000181	0.00204	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—TP53—liver cancer	0.00018	0.00204	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—TERT—liver cancer	0.00018	0.00204	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—HRAS—liver cancer	0.000172	0.00195	CbGpPWpGaD
Tadalafil—PDE11A—Hemostasis—AKT1—liver cancer	0.000171	0.00193	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—KDR—liver cancer	0.000165	0.00186	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MAPK14—liver cancer	0.000163	0.00185	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—ESR1—liver cancer	0.00016	0.00181	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—F2—liver cancer	0.000158	0.00179	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—CYP2E1—liver cancer	0.000157	0.00178	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—CYP2E1—liver cancer	0.000155	0.00176	CbGpPWpGaD
Tadalafil—PDE5A—Hemostasis—AKT1—liver cancer	0.000152	0.00172	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—APC—liver cancer	0.000152	0.00172	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PIK3CG—liver cancer	0.000152	0.00172	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—GGT1—liver cancer	0.000145	0.00164	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—BRAF—liver cancer	0.000142	0.00161	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PIK3CD—liver cancer	0.000133	0.00151	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—PIK3CA—liver cancer	0.000132	0.00149	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—SERPINE1—liver cancer	0.000132	0.00149	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—KRAS—liver cancer	0.00013	0.00148	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—GSTP1—liver cancer	0.00013	0.00147	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—GSTP1—liver cancer	0.000128	0.00145	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—PIK3CA—liver cancer	0.00012	0.00136	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—GSTM1—liver cancer	0.000119	0.00135	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—RAF1—liver cancer	0.000119	0.00135	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—GSTM1—liver cancer	0.000118	0.00133	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MTOR—liver cancer	0.000116	0.00131	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PIK3CB—liver cancer	0.000116	0.00131	CbGpPWpGaD
Tadalafil—CYP3A4—Biological oxidations—CYP1A1—liver cancer	0.000113	0.00128	CbGpPWpGaD
Tadalafil—CYP3A4—Metapathway biotransformation—CYP1A1—liver cancer	0.000112	0.00126	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—HRAS—liver cancer	0.000111	0.00126	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CDKN1B—liver cancer	0.000109	0.00123	CbGpPWpGaD
Tadalafil—PDE11A—GPCR downstream signaling—AKT1—liver cancer	0.000108	0.00122	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CASP3—liver cancer	0.000107	0.00121	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IL2—liver cancer	0.000107	0.00121	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—IL6—liver cancer	0.000106	0.0012	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CCND1—liver cancer	0.000104	0.00118	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—JUN—liver cancer	0.000104	0.00117	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CTNNB1—liver cancer	0.000103	0.00117	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MMP9—liver cancer	0.000101	0.00114	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—CDKN1A—liver cancer	0.000101	0.00114	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MAPK8—liver cancer	9.82e-05	0.00111	CbGpPWpGaD
Tadalafil—PDE11A—Signaling by GPCR—AKT1—liver cancer	9.79e-05	0.00111	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—VEGFA—liver cancer	9.06e-05	0.00103	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—STAT3—liver cancer	8.97e-05	0.00102	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—UGDH—liver cancer	8.46e-05	0.000958	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—MYC—liver cancer	8.34e-05	0.000944	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—TGFB1—liver cancer	8.32e-05	0.000942	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—EPT1—liver cancer	7.96e-05	0.000901	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—KRAS—liver cancer	7.71e-05	0.000872	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—TAT—liver cancer	7.54e-05	0.000854	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—PIK3CA—liver cancer	7.08e-05	0.000801	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—TP53—liver cancer	6.85e-05	0.000775	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—HRAS—liver cancer	6.55e-05	0.000741	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—IL6—liver cancer	6.27e-05	0.00071	CbGpPWpGaD
Tadalafil—PDE11A—Signaling Pathways—AKT1—liver cancer	5.78e-05	0.000655	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GLUL—liver cancer	5.13e-05	0.00058	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CPT1B—liver cancer	5.13e-05	0.00058	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NR1H4—liver cancer	4.94e-05	0.00056	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTA3—liver cancer	4.86e-05	0.00055	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTA4—liver cancer	4.45e-05	0.000503	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTA2—liver cancer	4.33e-05	0.00049	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTA1—liver cancer	4.18e-05	0.000473	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—NAT2—liver cancer	4.13e-05	0.000468	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ALDOB—liver cancer	3.96e-05	0.000449	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CRABP1—liver cancer	3.78e-05	0.000428	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HPGDS—liver cancer	3.3e-05	0.000374	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PSMD10—liver cancer	2.94e-05	0.000333	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PSMA4—liver cancer	2.94e-05	0.000333	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GOT2—liver cancer	2.86e-05	0.000324	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP2E1—liver cancer	2.69e-05	0.000305	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYCS—liver cancer	2.52e-05	0.000285	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GGT1—liver cancer	2.47e-05	0.00028	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GOT1—liver cancer	2.47e-05	0.00028	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTP1—liver cancer	2.22e-05	0.000251	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—HMOX1—liver cancer	2.19e-05	0.000248	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—GSTM1—liver cancer	2.04e-05	0.000231	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—CYP1A1—liver cancer	1.93e-05	0.000219	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—MTHFR—liver cancer	1.8e-05	0.000204	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PPARA—liver cancer	1.77e-05	0.0002	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PIK3CG—liver cancer	1.52e-05	0.000172	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PPARG—liver cancer	1.46e-05	0.000166	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PIK3CD—liver cancer	1.33e-05	0.000151	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—ALB—liver cancer	1.32e-05	0.000149	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PIK3CB—liver cancer	1.16e-05	0.000131	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—PIK3CA—liver cancer	7.08e-06	8.01e-05	CbGpPWpGaD
Tadalafil—CYP3A4—Metabolism—AKT1—liver cancer	5.78e-06	6.55e-05	CbGpPWpGaD
